In 2013, Mills and his team found out that nicotinamide mononucleotide (NMN) could manage type II diabetes.
ໃນປີ 2013, Mills ແລະທີມງານຂອງລາວໄດ້ພົບວ່າ nicotinamide mononucleotide (NMN) ສາມາດຄວບຄຸມໂລກເບົາຫວານຊະນິດ II ໄດ້.